Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Código da empresaNXLIW
Nome da EmpresaNexalin Technology Inc
Data de listagemSep 16, 2022
CEOMr. Mark White
Número de funcionários- -
Tipo de títulosCompany Warrant
Fim do ano fiscal- -
Endereço1776 Yorktown
CidadeHOUSTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal77056
Telefone18322600222
Sitehttps://nexalin.com
Código da empresaNXLIW
Data de listagemSep 16, 2022
CEOMr. Mark White
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados